Morgans says these small-cap ASX shares could rise 30% to 80%

MotleyFool

Mar 18

Having some exposure to the small side of the market can be a good thing for a balanced portfolio, if your risk tolerance allows for it. After all, the potential returns from small-cap ASX shares can ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2620027294"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620027294\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620027294?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 08:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620027294","market":"nz","top_or_hot":-1,"title":"Morgans says these small-cap ASX shares could rise 30% to 80%","media":"MotleyFool","content":"<div>\n<p>Having some exposure to the small side of the market can be a good thing for a balanced portfolio, if your risk tolerance allows for it.\nAfter all, the potential returns from small-cap ASX shares can ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/18/morgans-says-these-small-cap-asx-shares-could-rise-30-to-80/\">Source Link</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgans says these small-cap ASX shares could rise 30% to 80%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgans says these small-cap ASX shares could rise 30% to 80%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-18 08:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com.au/2026/03/18/morgans-says-these-small-cap-asx-shares-could-rise-30-to-80/><strong>MotleyFool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Having some exposure to the small side of the market can be a good thing for a balanced portfolio, if your risk tolerance allows for it.\nAfter all, the potential returns from small-cap ASX shares can ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/18/morgans-says-these-small-cap-asx-shares-could-rise-30-to-80/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CUV.AU","symbol_name":"CLINUVEL PHARMACEUTICALS LTD","start_time":0,"source_url":"https://www.fool.com.au/2026/03/18/morgans-says-these-small-cap-asx-shares-could-rise-30-to-80/","article_id":"2620027294","we_media_id":null,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/18/morgans-says-these-small-cap-asx-shares-could-rise-30-to-80/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620027294","pubTimestamp":1773795437,"columns":[],"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"Having some exposure to the small side of the market can be a good thing for a balanced portfolio, if your risk tolerance allows for it.After all, the potential returns from small-cap ASX shares can be significantly greater than those on offer with large caps.With that in mind, here are two small-cap shares that Morgans thinks could rise strongly from current levels. Let's see what it is recommending:. This biopharmaceuticals company disappointed Morgans during the first half, with softer-than-expected revenue growth and higher-than-expected cost growth.However, the broker remains positive, especially given that this small-cap ASX share trades on lower-than-normal multiples.As a result, the broker has put a speculative buy rating and $13.00 price target on its shares. This implies potential upside of 30% for investors from current levels. It said:. Whilst we downgrade our FY26-17 EBITDA forecasts by 10-20% reflecting revised guidance, given RDY's robust pipeline, potential catalysts , ","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"CUV.AU":"CLINUVEL PHARMACEUTICALS LTD","RDY.AU":"READYTECH HOLDINGS LTD","BK7067":"生物科技","BK7508":"医药生物股","BK7016":"应用软件"},"translate_title":"摩根表示这些澳大利亚证券交易所小盘股可能上涨30%至80%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CUV.AU":1,"RDY.AU":1},"content_text":"Having some exposure to the small side of the market can be a good thing for a balanced portfolio, if your risk tolerance allows for it.\nAfter all, the potential returns from small-cap ASX shares can be significantly greater than those on offer with large caps.\nWith that in mind, here are two small-cap shares that Morgans thinks could rise strongly from current levels. Let's see what it is recommending:\nImage source: Getty Images\nClinuvel Pharmaceuticals Ltd (ASX: CUV)\nThis biopharmaceuticals company disappointed Morgans during the first half, with softer-than-expected revenue growth and higher-than-expected cost growth.\nHowever, the broker remains positive, especially given that this small-cap ASX share trades on lower-than-normal multiples.\nAs a result, the broker has put a speculative buy rating and $13.00 price target on its shares. This implies potential upside of 30% for investors from current levels. It said:\nCUV delivered a softer result that landed below expectations, with top line underperformance and operational cost growth materially outpacing revenue. The combination of slower revenue growth, heavier opex, FX drag, and margin compression makes for an underwhelming print relative to expectations.\nWhile fundamentally cheap with a large cash balance providing valuation support and trading well below historical multiples, the outlook continues to hinge on clinical catalysts and a change in sentiment (strategic direction driven) which we view is unlikely to shift meaningfully in the near term. Minor downgrades due to higher OpEx base and adjustments to WACC. Our target price reduces to A$13 (from A$14) but retain a SPECULATIVE BUY recommendation.\nReadytech Holdings Ltd (ASX: RDY)\nAnother small-cap ASX share that Morgans is positive on is enterprise software company Readytech.\nWhile it also delivered a half-year result that was softer than expected, the broker remains bullish due to its cheap valuation and strong sales pipeline. It has a speculative buy rating and $2.20 price target on Readytech's shares, which suggests that upside of almost 80% is possible over the next 12 months. Morgans said:\nRDY's 1H26 result and revised outlook came in softer than expected, with Underlying EBITDA of $17.5m / Cash EBITDA of $7.5m ~6% behind MorgF. Whilst RDY's enterprise strategy remains on track, the group indicated that increased churn in 1H26 along with more protracted implementation/sale conversion have led to an FY26 guidance downgrade and the withdrawal of its longer-term targets.\nWhilst we downgrade our FY26-17 EBITDA forecasts by 10-20% reflecting revised guidance, given RDY's robust pipeline, potential catalysts (VIC TAFE decision and likely increased corporate appeal), we move to a SPECULATIVE BUY rating, with a revised price target of $2.20/sh (previously $3.00/sh).","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}